Australian Technical Advisory Group on Immunisation

Australian Technical Advisory Group on Immunisation
Name	Australian Technical Advisory Group on Immunisation
Abbreviation	ATAGI
Formation	1997
Headquarters	Canberra
Leader title	Chair
Leader name	Professor Brendon D. High (example)
Parent organization	Department of Health and Aged Care

Australian Technical Advisory Group on Immunisation is the principal Australian expert advisory body providing technical advice on vaccines and immunisation to the Department of Health and Aged Care, federal ministers such as the Minister for Health and Aged Care (Australia), and state and territory health departments including New South Wales Health and Victoria (Australia). It synthesises evidence from international organisations such as the World Health Organization, the Centers for Disease Control and Prevention, and the European Centre for Disease Prevention and Control to inform national immunisation policy used by programs like the National Immunisation Program (Australia) and services delivered by bodies such as Primary Health Networks (Australia), Australian Technical Advisory Group on Immunisation.

History

ATAGI was established in the late 20th century amid reforms to Australian public health systems including the National Health and Medical Research Council and the restructuring of the Australian Government Department of Health; its formation followed precedents set by advisory committees such as the Advisory Committee on Immunization Practices in the United States and the Joint Committee on Vaccination and Immunisation in the United Kingdom. Its early work intersected with national responses to events including the H1N1 influenza pandemic of 2009, the reorganisation of the National Immunisation Program (Australia) schedule, and broader initiatives led by organisations like the Australian Technical Advisory Group on Immunisation and collaborations with the Commonwealth Scientific and Industrial Research Organisation. Over time ATAGI contributed to major national decisions on vaccines for pathogens such as human papillomavirus, rotavirus, and pneumococcus while interacting with regulators including the Therapeutic Goods Administration.

Role and responsibilities

ATAGI provides technical advice on vaccine policy, including inclusion on the National Immunisation Program (Australia), prioritisation during supply constraints such as those experienced during the COVID-19 pandemic, and guidance on clinical use comparable to advice from the Advisory Committee on Immunization Practices and the European Medicines Agency. It evaluates safety signals reported to the Therapeutic Goods Administration and works with surveillance systems like the Australian Immunisation Register and the Notifiable Diseases Surveillance System to recommend measures addressing outbreaks such as those caused by measles, pertussis, and meningococcal disease. ATAGI issues clinical guidance relevant to practitioners registered with the Australian Health Practitioner Regulation Agency and liaises with academic institutions such as The University of Melbourne and Monash University for methodological support.

Membership and organization

ATAGI's membership comprises experts drawn from clinical medicine, epidemiology, vaccine safety, public health and indigenous health, nominated by institutions including the National Health and Medical Research Council, state health departments, and universities such as The University of Sydney and Australian National University. The group includes a Chair, technical subcommittees, and ex officio representatives from agencies like the Therapeutic Goods Administration and the Communicable Diseases Network Australia. Members often hold appointments at hospitals such as Royal Melbourne Hospital and research organisations including Murdoch Children's Research Institute, with roles aligned to professional colleges like the Royal Australasian College of Physicians and the Australian Medical Association.

Advisory processes and decision-making

ATAGI operates through scheduled meetings, evidence reviews, and formal deliberations that incorporate methods used by international peers such as the World Health Organization Strategic Advisory Group of Experts and systems used by the Centers for Disease Control and Prevention Advisory Committee. It commissions systematic reviews from academic partners including The George Institute for Global Health and draws on surveillance data from the Australian Immunisation Register, vaccine safety reports to the Therapeutic Goods Administration, and modelling from agencies such as the Australian Bureau of Statistics. Recommendations are reached through consensus or majority vote, documented in statements that inform ministers in documents prepared for bodies like the Australian Parliament and state health ministers at meetings of the Australian Health Ministers' Advisory Council.

Vaccine recommendations and policies

ATAGI makes vaccine-specific recommendations for inclusion on the National Immunisation Program for vaccines against agents including influenza, SARS-CoV-2, human papillomavirus, and pneumococcus, and issues advice on dosing schedules, contraindications, and booster strategies similar to guidance from Public Health England and the European Centre for Disease Prevention and Control. During the COVID-19 pandemic, ATAGI provided prioritisation frameworks for vaccine allocation and clinical guidance on the use of vaccines authorised by regulators such as the Therapeutic Goods Administration and influenced procurement decisions undertaken by agencies like the Department of Finance (Australia). It also advises on targeted strategies for high-risk groups including indigenous populations served by organisations such as Aboriginal Health Services and aged-care residents in facilities regulated under the Aged Care Act 1997.

Public communication and impact

ATAGI publishes statements, clinical guidance, and FAQs that are disseminated via the Department of Health and Aged Care website and amplified by state health agencies such as NSW Health and advocacy groups including the Immunisation Coalition. Its communications inform healthcare providers registered with bodies like the Nursing and Midwifery Board of Australia and influence public understanding alongside media organisations such as the Australian Broadcasting Corporation and newspapers like The Sydney Morning Herald. ATAGI's guidance has shaped uptake trends observed in surveillance datasets maintained by the Australian Immunisation Register and influenced policy debates in forums such as the Australian Health Ministers' Advisory Council and parliamentary inquiries.

Controversies and criticisms

ATAGI has faced scrutiny over decisions during high-profile events such as the COVID-19 pandemic and vaccine safety responses to adverse events associated with certain products, prompting debate in outlets like The Australian and inquiries involving entities such as the Australian National Audit Office. Critics have raised issues about transparency, timing of recommendations, and communication with vulnerable communities including indigenous groups represented by bodies like the National Aboriginal Community Controlled Health Organisation; defenders cite ATAGI's reliance on evidence and coordination with regulators such as the Therapeutic Goods Administration and international partners like the World Health Organization. Ongoing evaluations of ATAGI's processes have referenced methodologies used by advisory bodies such as the Joint Committee on Vaccination and Immunisation and called for strengthened links with research organisations including The Kirby Institute and expanded public engagement.

Category:Medical and health organisations based in Australia